DiaMedica Therapeutics (DMAC) Change in Account Payables (2018 - 2026)
DiaMedica Therapeutics (DMAC) reported Change in Account Payables of $1.8 million for Q1 2026, up 220.63% on a YoY basis from $567000.0 in Q1 2025, and up 508.54% quarter-over-quarter from -$445000.0 in Q4 2025.
DiaMedica Therapeutics (DMAC) Change in Account Payables (2018 - 2026) Analysis & Trends
DiaMedica Therapeutics has reported Change in Account Payables for 9 years, with the latest figure at $1.8 million in Q1 2026.
- For the quarter ending Q1 2026, Change in Account Payables rose 220.63% year-over-year to $1.8 million; the trailing twelve-month figure through Mar 2026 stood at $1.8 million (up 125.79% YoY), and the FY2025 full-year result was $535000.0, up 3721.43% from the prior year.
- Change in Account Payables for Q1 2026 stood at $1.8 million, up from -$445000.0 in the prior quarter.
- The five-year high for Change in Account Payables was $1.8 million in Q1 2026, with the low at -$924000.0 in Q2 2023.
- Historically, Change in Account Payables has averaged $163764.7 across 5 years, with a median of $43000.0 in 2024.
- Annual changes were most pronounced in 2024 — Change in Account Payables jumped 5785.71% — and 2025, when it sank 672.09%.
- DiaMedica Therapeutics' Change in Account Payables stood at -$130000.0 in 2022, then jumped by 148.46% to $63000.0 in 2023, then plunged by 466.67% to -$231000.0 in 2024, then tumbled by 92.64% to -$445000.0 in 2025, then surged by 508.54% to $1.8 million in 2026.
- The last three Change in Account Payables figures came in at $1.8 million (Q1 2026), -$445000.0 (Q4 2025), and $659000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | -3.26 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 35.60 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -9.42 Mn |
| 10 | DiaMedica Therapeutics | 285.11 Mn | 233.77 Mn | - | 1.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.82 Mn |
| Mar 31, 2026 | 1.82 Mn |
| Dec 31, 2025 | -445,000.00 |
| Dec 31, 2025 | -445,000.00 |
| Sep 30, 2025 | 659,000.00 |
| Sep 30, 2025 | 659,000.00 |
| Jun 30, 2025 | -246,000.00 |
| Jun 30, 2025 | -246,000.00 |
| Mar 31, 2025 | 567,000.00 |
| Mar 31, 2025 | 567,000.00 |
| Dec 31, 2024 | -231,000.00 |
| Dec 31, 2024 | -231,000.00 |
| Sep 30, 2024 | 412,000.00 |
| Sep 30, 2024 | 412,000.00 |
| Jun 30, 2024 | 43,000.00 |
| Jun 30, 2024 | 43,000.00 |
| Mar 31, 2024 | -210,000.00 |
| Mar 31, 2024 | -210,000.00 |
| Dec 31, 2023 | 63,000.00 |
| Dec 31, 2023 | 63,000.00 |